



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/723,368		
		Filing Date	November 26, 2003		
		First Named Inventor	HSU, SHEAU YU TEDDY		
		Art Unit	1614		
Sheet	1	of	3	Examiner Name	
				Attorney Docket Number	STAN-284

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), <small>publisher, city and/or country where published</small>	T ²
RV		ALLEN et al., IDENTIFICATION OF TWO CLASSES OF PROLACTIN- RELEASING FACTORS IN INTERMEDIATE LOBE TUMORS FROM TRANSGENIC MICE, Endocrinology, (1995), 136:3093-3099	
		BEN-JONATHAN et al., DOPAMINE AS A PROLACTIN (PRL) INHIBITOR, Endocr. Rev., (2001), 22(6): 724-763	
		CHRISTOPOULOS et al., MULTIPLE AMYLIN RECEPTORS ARISE FROM RECEPTOR ACTIVITY-MODIFYING PROTEIN INTERACTION WITH THE CALCITONIN RECEPTOR GENE PRODUCT, Mol. Pharmacol., (1999), 56:235-242	
		GenBank entry AF529213	
16		HAY et al., KNOCKOUTS AND TRANSGENICS CONFIRM THE IMPORTANCE OF ADRENOMEDULLIN IN THE VASCULATURE, Trends Pharmacol. Sci., (2001), 22:57-59	

Examiner Signature	RB M	Date Considered	11-06-04
-----------------------	------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/723,368		
		Filing Date	November 26, 2003		
		First Named Inventor	HSU, SHEAU YU TEDDY		
		Group Art Unit	1614		
Sheet	2	of	3	Examiner Name	
				Attorney Docket Number	STAN-284

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RR		KRUGER et al., CALCITONIN GENE-RELATED PEPTIDE (CGRP) IN THE RAT CENTRAL NERVOUS SYSTEM: PATTERNS OF IMMUNOREACTIVITY AND RECEPTOR BINDING SITES, Brain Res., (1988), 463:223-244	
		LAUDON et al., PROLACTIN-RELEASING FACTOR: CELLULAR ORIGIN IN THE INTERMEDIATE LOBE OF THE PITUITARY, Endocrinology, (1990), 126(6):3185-3192	
		MCLATCHIE et al., RAMPS REGULATE THE TRANSPORT AND LIGAND SPECIFICITY OF THE CALCITONIN-RECEPTOR-LIKE RECEPTOR, Nature, (1998), 393:333-339	
		MEERAN et al., CIRCULATING ADRENOMEDULLIN DOES NOT REGULATE SYSTEMIC BLOOD PRESSURE BUT INCREASES PLASMA PROLACTIN AFTER INTRAVENOUS INFUSION IN HUMANS: A PHARMACOKINETIC STUDY, J. Clin. Endocrinol. Metab., (1997), 82(1):95-100	
		MULDER et al., ISLET AMYLOID POLYPEPTIDE (AMYLIN)-DEFICIENT MICE DEVELOP A MORE SEVERE FORM OF ALLOXAN-INDUCED DIABETES, Am. J. Physiol. Endocrinol. Metab., (2000), 278:E684-E691	
		POYNER et al., INTERNATIONAL UNION OF PHARMACOLOGY. XXXII. THE MAMMALIAN CALCITONIN GENE-RELATED PEPTIDES, ADRENOMEDULLIN, AMYLIN, AND CALCITONIN RECEPTORS, Pharmacol. Rev., (2002), 54(2):233-246	

Examiner Signature	RS Mow	Date Considered	11-04-04
-----------------------	--------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/723,368
		Filing Date	November 26, 2003
		First Named Inventor	HSU, SHEAU YU TEDDY
		Group Art Unit	1614
		Examiner Name	
Sheet 2 of 3	Attorney Docket Number	STAN-284	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RB		SALMON et al., MODULATION OF MORPHINE ANALGESIA IN α CGRP MUTANT MICE, Neuroreport, (1999), 10(4):849-854	
		SALMON et al., ALTERED NEUROADAPTATION IN OPIATE DEPENDENCE AND NEUROGENIC INFLAMMATORY NOCICEPTION IN α CGRP - DEFICIENT MICE, Nat. Neurosci., (2001), 4:357-358	
		SHINDO et al., VASCULAR ABNORMALITIES AND ELEVATED BLOOD PRESSURE IN MICE LACKING ADRENOMEDULLIN GENE, Circulation, (2001), 104:1964-197	
		ZHANG et al., ARTHRITIC CALCITONIN/ α CALCITONIN GENE-RELATED PEPTIDE KNOCKOUT MICE HAVE REDUCED NOCICEPTIVE HYPERSENSITIVITY, Pain, (2001), 89:265-273	

Examiner Signature	<i>RB</i>	Date Considered	11-06-04
--------------------	-----------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.